Mitsuno M - Search Results

1

Hypoxia-inducible factor-1alpha expression predicts the response to 5-fluorouracil-based adjuvant chemotherapy in advanced gastric cancer.

Nakamura J, Kitajima Y, Kai K, Mitsuno M, Ide T, Hashiguchi K, Hiraki M, Miyazaki K. Nakamura J, et al. Among authors: mitsuno m. Oncol Rep. 2009 Oct;22(4):693-9. doi: 10.3892/or_00000489. Oncol Rep. 2009. PMID: 19724845

2

Tumor-stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c-Met pathway.

Ide T, Kitajima Y, Miyoshi A, Ohtsuka T, Mitsuno M, Ohtaka K, Koga Y, Miyazaki K. Ide T, et al. Among authors: mitsuno m. Int J Cancer. 2006 Dec 15;119(12):2750-9. doi: 10.1002/ijc.22178. Int J Cancer. 2006. PMID: 16998831

3

The hypoxic environment in tumor-stromal cells accelerates pancreatic cancer progression via the activation of paracrine hepatocyte growth factor/c-Met signaling.

Ide T, Kitajima Y, Miyoshi A, Ohtsuka T, Mitsuno M, Ohtaka K, Miyazaki K. Ide T, et al. Among authors: mitsuno m. Ann Surg Oncol. 2007 Sep;14(9):2600-7. doi: 10.1245/s10434-007-9435-3. Epub 2007 May 30. Ann Surg Oncol. 2007. PMID: 17534684

4

Aberrant methylation of p16 predicts candidates for 5-fluorouracil-based adjuvant therapy in gastric cancer patients.

Mitsuno M, Kitajima Y, Ide T, Ohtaka K, Tanaka M, Satoh S, Miyazaki K. Mitsuno M, et al. J Gastroenterol. 2007 Nov;42(11):866-73. doi: 10.1007/s00535-007-2113-1. Epub 2007 Nov 22. J Gastroenterol. 2007. PMID: 18008030 Clinical Trial.

5

Helicobacter pylori infection is an independent risk factor for Runx3 methylation in gastric cancer.

Kitajima Y, Ohtaka K, Mitsuno M, Tanaka M, Sato S, Nakafusa Y, Miyazaki K. Kitajima Y, et al. Among authors: mitsuno m. Oncol Rep. 2008 Jan;19(1):197-202. Oncol Rep. 2008. PMID: 18097595

6

Expression of the hMLH1 gene is a possible predictor for the clinical response to 5-fluorouracil after a surgical resection in colorectal cancer.

Ide T, Kitajima Y, Ohtaka K, Mitsuno M, Nakafusa Y, Miyazaki K. Ide T, et al. Among authors: mitsuno m. Oncol Rep. 2008 Jun;19(6):1571-6. Oncol Rep. 2008. PMID: 18497967

7

Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma.

Ohtaka K, Kohya N, Sato K, Kitajima Y, Ide T, Mitsuno M, Miyazaki K. Ohtaka K, et al. Among authors: mitsuno m. Oncol Rep. 2008 Aug;20(2):279-86. Oncol Rep. 2008. PMID: 18636187

8

Aberrant gene methylation in the lymph nodes provides a possible marker for diagnosing micrometastasis in gastric cancer.

Hiraki M, Kitajima Y, Sato S, Mitsuno M, Koga Y, Nakamura J, Hashiguchi K, Noshiro H, Miyazaki K. Hiraki M, et al. Among authors: mitsuno m. Ann Surg Oncol. 2010 Apr;17(4):1177-86. doi: 10.1245/s10434-009-0815-8. Epub 2009 Dec 3. Ann Surg Oncol. 2010. PMID: 19957042

9

Tranilast strongly sensitizes pancreatic cancer cells to gemcitabine via decreasing protein expression of ribonucleotide reductase 1.

Mitsuno M, Kitajima Y, Ohtaka K, Kai K, Hashiguchi K, Nakamura J, Hiraki M, Noshiro H, Miyazaki K. Mitsuno M, et al. Int J Oncol. 2010 Feb;36(2):341-9. Int J Oncol. 2010. PMID: 20043067

10

Role of ASC in hypoxia-mediated cell death in pancreatic cancer.

Ohtsuka T, Mitsuno M, Kitajima Y, Ide T, Lee SW, Miyazaki K. Ohtsuka T, et al. Among authors: mitsuno m. Mol Med Rep. 2008 Nov-Dec;1(6):827-31. doi: 10.3892/mmr_00000035. Mol Med Rep. 2008. PMID: 21479491

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

118 results

Search Page

Filters